Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess, over a period of 12 months, the effect on
weight loss and weight maintenance of rimonabant 10 mg in comparison with rimonabant 20 mg in
overweight/obese patients after an initial treatment period of 6 months with rimonabant 20
mg.
Secondary objectives are to assess the effect of rimonabant over a period of 12 months on
waist circumference, high-density lipoprotein (HDL)-Cholesterol and triglycerides (TG),
fasting plasma glucose (FPG), fasting insulin and to evaluate the long-term safety and
tolerability of rimonabant 10 mg and 20 mg over a period of 12 months after randomization in
overweight/obese patients.